Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies
Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company,
---
Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025
